Metastatic clear-cell renal cell carcinoma: a frequent NOTCH1 mutation predictive of response to anti-NOTCH1 CB-103 treatment.
Fiche publication
Date publication
mai 2023
Journal
Experimental hematology & oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr FEUGEAS Jean-Paul
Tous les auteurs :
Bui TO, Angeli E, El Bouchtaoui M, Gapihan G, Dao VT, Paris J, Leboeuf C, Soussan M, Villarese P, Ziol M, Van Glabeke E, Le TH, Feugeas JP, Janin A, Bousquet G
Lien Pubmed
Résumé
Clear-cell renal cell carcinomas (ccRCCs) are malignant tumors with high metastatic potential and resistance to treatments occurs almost constantly. Compared to primary tumors, there are still limited genomic data that has been obtained from metastatic samples.
Mots clés
Anti-NOTCH1 treatment, Biomarker, CB-103, Metastatic clear-cell renal cell carcinoma, NOTCH1 mutation
Référence
Exp Hematol Oncol. 2023 05 15;12(1):46